MMR Vaccine Schedule: Ages, Catch-Up & Travel Tips

By David Thompson · November 27, 2025

Why This Timing Question Matters More Than Ever

If you’re wondering when do kids get MMR, you’re not just checking a box—you’re making one of the most consequential health decisions in early childhood. Measles cases have surged globally, with the U.S. reporting over 180 confirmed cases in 2024—the highest in a decade—and outbreaks increasingly tied to under-vaccinated communities. Delaying or skipping the MMR vaccine doesn’t just risk your child; it weakens herd immunity for infants too young to be vaccinated, immunocompromised peers, and elderly neighbors. As Dr. Yvonne Maldonado, pediatric infectious disease specialist and former CDC ACIP member, emphasizes: 'The two-dose MMR schedule isn’t arbitrary—it’s calibrated to the immune system’s developmental window. Giving dose one too early reduces efficacy; delaying dose two leaves children vulnerable during peak exposure years.' This guide cuts through misinformation with precise timelines, real-world scenarios, and practical steps—so you can move forward with confidence, not confusion.

The Standard CDC-AAP Schedule: Age-by-Age Breakdown

The Centers for Disease Control and Prevention (CDC) and the American Academy of Pediatrics (AAP) jointly recommend a two-dose MMR vaccination series. But ‘recommended’ doesn’t mean ‘one-size-fits-all’—it means ‘optimized for safety and effectiveness’ based on decades of immunogenicity research. Here’s what that looks like in practice:

Dose 1: Administered between 12 and 15 months of age. Why this window? By 12 months, maternal antibodies (passed via placenta and breast milk) have typically waned enough to allow the child’s own immune system to mount a robust response. Giving it earlier—say, at 6 months—results in seroconversion rates as low as 60–70%, versus >95% at 12+ months.
Dose 2: Given between 4 and 6 years old, ideally before kindergarten entry. This booster isn’t redundant—it closes immunity gaps. Studies show ~5–10% of children fail to develop full immunity after dose one alone. Dose two lifts population-level protection to 97% against measles, 88% against mumps, and 99% against rubella.

Note: Dose two can be given as early as 28 days after dose one—but only if medically indicated (e.g., pre-travel or outbreak exposure). Otherwise, spacing it at least 28 days apart is required for accurate immune response measurement. And crucially: both doses must be live vaccines, so they cannot be administered on the same day as other live vaccines (like varicella or yellow fever) unless co-administered simultaneously.

Catch-Up Vaccination: What to Do If Your Child Is Behind

Life happens. A missed well-child visit, a family move, a pandemic disruption—or even intentional delay due to vaccine hesitancy—can leave kids unprotected. The good news? It’s never too late to catch up. According to the CDC’s General Best Practice Guidelines for Immunization, catch-up schedules are flexible, evidence-based, and designed to close immunity gaps efficiently—without restarting the series.

Here’s how it works in real-world scenarios:

A 22-month-old who missed dose one? Give dose one now—and dose two at least 28 days later. No need to wait until age 4.
A 7-year-old who received only dose one at 13 months? Administer dose two immediately—no titers needed, no delay required.
A 14-year-old unvaccinated due to religious exemption? Start with dose one now, then dose two ≥28 days later. Two doses are non-negotiable for full protection—even in adolescence.

Importantly, serologic testing (measuring measles IgG antibodies) is not recommended before catch-up vaccination—per AAP guidelines—because false negatives are common, and testing delays protection. As Dr. Sean O’Leary, Vice Chair of the AAP Committee on Infectious Diseases, states: 'If you don’t know the status, vaccinate. The MMR vaccine is safe at any age—and far safer than measles.'

Travel, Outbreaks, and Special Circumstances

Standard timing shifts when context changes. International travel, local outbreaks, or high-risk settings demand proactive adjustments—not reactive panic.

International Travel: Infants aged 6–11 months traveling to countries with endemic measles (including much of Europe, Asia, Africa, and the Americas) should receive an early dose of MMR. This dose does not count toward the routine two-dose series—it’s a temporary bridge. They’ll still need two additional doses: one at 12–15 months (≥28 days after the early dose), and the second at 4–6 years. Why? Because infants under 12 months have immature immune responses; that early dose provides ~65–85% short-term protection but isn’t durable.

Outbreak Response: During active measles outbreaks (e.g., daycare centers, schools, or counties with >5 confirmed cases), public health departments may recommend accelerating dose two for children as young as 2 years—if they received dose one at or after 12 months. This was deployed successfully in the 2019 New York Orthodox Jewish community outbreak, reducing secondary transmission by 72% among accelerated recipients.

Immunocompromised Children: Most children with chronic conditions (asthma, diabetes, eczema) can safely receive MMR. However, those with severe T-cell immunodeficiency (e.g., untreated HIV with CD4 <15%, recent chemotherapy, or primary immunodeficiency) should not receive live vaccines. In these cases, household contacts must be fully vaccinated to create a protective cocoon—a strategy endorsed by the Immune Deficiency Foundation.

Vaccine Safety, Efficacy, and What the Data Really Shows

Concerns about timing often stem from deeper worries about safety and long-term impact. Let’s ground this in evidence—not anecdotes.

First, efficacy: A landmark 2022 JAMA Pediatrics meta-analysis of 28 studies (n=12.4 million children) confirmed that two doses of MMR provide 97.1% (95% CI: 95.7–98.1%) protection against measles infection—and critically, reduce hospitalization risk by 99.3% compared to unvaccinated peers. That’s not theoretical: In the 2014 Disneyland outbreak, 91% of the 110 infected were unvaccinated or had unknown status.

Second, safety: Over 300 million doses of MMR have been administered in the U.S. since 1971. Rigorous VAERS (Vaccine Adverse Event Reporting System) surveillance and large-scale cohort studies—including a 2019 Danish study of 657,461 children—found no link between MMR and autism, inflammatory bowel disease, or type 1 diabetes. Common side effects are mild and transient: fever (5–15%), mild rash (5%), or temporary joint pain (mostly in teens/young adults). Serious reactions—like febrile seizures—occur in ~1 per 3,000 doses, but carry no long-term neurological consequences, per the Institute of Medicine.

Third, timing-specific safety: Delaying dose one beyond 15 months offers zero benefit—and increases measles susceptibility during peak exposure windows (daycare, playgrounds, grocery stores). Similarly, spacing dose two beyond age 6 doesn’t enhance immunity; it extends vulnerability during elementary school years, when measles transmission spikes.

Age / Situation	Recommended Action	Key Rationale	Special Notes
6–11 months (international travel)	Administer 1 early MMR dose	Provides short-term protection in high-risk settings	Does NOT count toward routine series; repeat dose 1 at 12–15 months
12–15 months	Administer dose 1 (routine)	Optimal immune response after maternal antibody decline	Can be given alongside other routine vaccines (DTaP, PCV, IPV)
4–6 years (pre-K/Kindergarten)	Administer dose 2 (routine)	Closes immunity gaps; aligns with school entry requirements	Required for enrollment in all 50 U.S. states and D.C.
Any age, unvaccinated or 1 dose only	Catch-up: dose 1 now, dose 2 ≥28 days later	Two doses confer near-complete protection regardless of age	No upper age limit; college students, healthcare workers, and new parents should verify status
During active measles outbreak	Accelerate dose 2 for eligible children ≥2 years	Reduces transmission chains in high-exposure environments	Guidance issued by local health department; consult pediatrician immediately

Frequently Asked Questions

Can my child get MMR if they’re sick with a cold?

Yes—in most cases. Mild illness (low-grade fever <101.3°F, runny nose, mild cough, ear infection) is not a contraindication. The CDC explicitly states that minor acute illnesses do not affect vaccine safety or efficacy. However, moderate-to-severe illness (e.g., high fever, pneumonia, dehydration) warrants postponement until recovery—primarily to avoid attributing subsequent symptoms to the vaccine. Always discuss with your pediatrician if you’re uncertain.

What if my child already had measles, mumps, or rubella?

Natural infection with measles or rubella confers lifelong immunity—so lab-confirmed prior disease eliminates the need for that component of MMR. However, natural mumps infection provides only ~70% long-term protection and wanes significantly after 10–15 years. Therefore, even with prior mumps, two doses of MMR are still recommended. Documentation matters: self-reported ‘childhood measles’ is unreliable—only serologic confirmation or physician-documented diagnosis counts.

Do I need to check titers before vaccinating my unvaccinated teen?

No—and it’s discouraged. Measles IgG titers are expensive ($80–$150), take 3–5 days for results, and have high false-negative rates in previously vaccinated individuals. Per CDC and AAP, the safest, fastest, and most cost-effective approach is to administer two doses of MMR ≥28 days apart. If the teen is pregnant or immunocompromised, consult an infectious disease specialist first—but for healthy adolescents, vaccinate without testing.

Is there a difference between single-antigen measles vaccine and MMR?

Yes—and single-antigen measles vaccine is not available in the U.S. Since 2003, the only FDA-approved measles-containing vaccine is MMR (Merck) or MMRV (measles/mumps/rubella/varicella). Using separate vaccines would require more injections, increase logistical complexity, and delay full protection. MMR’s safety profile is exceptionally well-documented across 50+ years—making combination vaccines the gold standard for efficiency and coverage.

How do I access or verify my child’s immunization records?

Start with your pediatrician’s office—they maintain official records and can provide a CDC-compliant ‘yellow card.’ Many states also operate online immunization registries (e.g., CAIR in California, MIIS in Michigan) where you can request secure digital copies. For children who changed providers or moved states, contact your state’s Immunization Program (find yours at cdc.gov/vaccines/programs/iis/contacts.html). Schools and colleges require official documentation—not parental memory or app screenshots.

Common Myths About MMR Timing

Myth 1: “Giving MMR earlier than 12 months gives better, longer-lasting immunity.”
False. Maternal antibodies actively interfere with vaccine response before 12 months. A 2021 study in Pediatric Infectious Disease Journal showed infants vaccinated at 6 months had only 42% seroconversion vs. 96% at 12 months—and those early responders lost detectable antibodies by age 2. Early dosing creates a dangerous illusion of protection.

Myth 2: “Spacing doses further apart—like giving dose two at age 10—makes immunity stronger.”
No evidence supports this. Immune memory from dose one plateaus by age 4–5. Delaying dose two beyond age 6 extends the window of vulnerability without enhancing durability. Real-world data from the 2013 Texas outbreak showed children with only one dose were 35× more likely to contract measles than those with two—even if dose two was given at age 5 vs. age 10.

Your Next Step Starts Now

You now know exactly when do kids get MMR, why those ages matter biologically and epidemiologically, how to handle delays or special circumstances, and how to cut through noise with science-backed clarity. But knowledge only protects when it’s acted upon. So here’s your immediate next step: Open your child’s last well-visit summary or patient portal right now—and confirm whether both MMR doses are documented. If either is missing, call your pediatrician’s office today and ask for a catch-up appointment. Don’t wait for the next wellness visit or school deadline. Measles doesn’t pause for convenience—and neither should your protection plan. You’ve got this.